Skip to main content
Back
Watch Compare

IGC Pharma, Inc.

Data quality: 100%
IGC
NYSE Manufacturing Chemicals
$0.30
▼ $0.00 (-0.33%)
Mkt Cap: 28.20 M
Price
$0.29
Mkt Cap
28.20 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -0.82% annually over 5 years
Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -5.49 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 34.57%
Capital efficient — spends only 2.70% of revenue on capex

Growth

Revenue Growth (5Y)
-0.82%
Below sector avg (1.82%)
Revenue (1Y)-35.39%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-48.99%
Above sector avg (-54.01%)
ROIC-91.75%
Net Margin-493.04%
Op. Margin-1192.19%

Safety

Debt / Equity
0.02
Below sector avg (0.30)
Current Ratio1.32
Interest Coverage-2797.67

Valuation

PE (TTM)
-8.12
Below sector avg (-1.49)
P/B Ratio3.48
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -8.1 -1.5
P/B 3.5 1.6
ROE % -49.0 -54.0
Net Margin % -493.0 -41.5
Rev Growth 5Y % -0.8 1.8
D/E 0.0 0.3

Analyst Price Target

2 analysts
Buy
Current
$0.30
+1275.0%
Target
$4.13
$3.00
$4.13
$5.25
Forecast
Forward EPS -$0.09

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2026 — 0.0 —

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q32025 -$0.02 -$0.02 0.0%
Q22025 -$0.03 -$0.02 +20.0%
Q12025 -$0.02 -$0.01 +50.0%
Q42024 -$0.03 -$0.02 +33.3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -35.39% Revenue Growth (3Y) -2.33%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -0.82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 704,000.0 Net Income (TTM) -3.47 M
ROE -48.99% ROA -39.25%
Gross Margin 26.85% Operating Margin -1192.19%
Net Margin -493.04% Free Cash Flow (TTM) -5.49 M
ROIC -91.75% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 1.32
Interest Coverage -2797.67 Asset Turnover 0.08
Working Capital 490,000 Tangible Book Value 3.21 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8.12 Forward P/E N/A
P/B Ratio 3.48 P/S Ratio 40.05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -19.46%
Market Cap 28.20 M Enterprise Value 27.23 M
Per Share
EPS (Diluted TTM) -0.03 Revenue / Share 0.01
FCF / Share -0.06 OCF / Share -0.06
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2.70% FCF Conversion 158.11%
SBC-Adj. FCF -14.49 M Growth Momentum -34.57

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 869,000.0 1.35 M 911,000.0 397,000.0 898,000.0
Net Income -4.15 M -13.00 M -11.51 M -15.02 M -8.81 M
EPS (Diluted) -0.05 — — — —
Gross Profit 297,000.0 733,000.0 442,000.0 194,000.0 113,000.0
Operating Income -7.75 M -9.80 M -11.57 M -15.43 M -8.72 M
EBITDA — — — — —
R&D Expenses 3.92 M 3.77 M 3.46 M 2.33 M 929,000.0
SG&A Expenses 4.12 M 6.76 M 8.55 M 13.29 M 7.91 M
D&A 324,000.0 637,000.0 657,000.0 651,000.0 478,000.0
Interest Expense 4,000.0 5,000.0 5,000.0 5,000.0 3,000.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9.71 M 9.90 M 17.18 M 26.83 M 35.87 M
Total Liabilities 2.29 M 2.58 M 2.27 M 2.94 M 3.06 M
Shareholders' Equity 7.42 M 7.32 M 14.91 M 23.89 M 32.80 M
Total Debt 134,000.0 140,000.0 144,000.0 147,000.0 580,000.0
Cash & Equivalents 900,000.0 1.20 M 3.20 M 10.46 M 14.55 M
Current Assets 1.79 M 3.71 M 6.47 M 15.11 M 23.52 M
Current Liabilities 2.16 M 2.34 M 1.90 M 2.44 M 2.37 M